We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
German biotech maintains guidance but prepares for fall in sales because of jab oversupply
On paper the obesity drug market is huge but mass adoption of the treatments would strain health budgets
Late-stage trial of Tirzepatide could be a ‘potential breakthrough’ in treatment, says US drugmaker
The final instalment of our series on innovation in European healthcare examines the effects of the slump in biotech valuations and changes in EU health policy
‘Intricate dance’ under way to ensure simplified assessments of new medicines maintain quality and integrity
The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Move could boost global development of drugs to ease antimicrobial resistance
New drugs are needed as resistance grows but plans to improve incentives are too modest, executives say
Kate Bingham urges fund managers to step up investment in life sciences
To save lives and economies, we must make progress by drawing on lessons from Covid-19
Swiss drugmaker to license antiviral therapeutic after success in early-stage tests
Drugmakers set to take on GSK as they aim to replicate Covid jab success
Researchers say more than 100m suffer ill effects for at least 12 weeks
Lower effectiveness of vaccines against Omicron makes need for antivirals more urgent, says UK BioIndustry Association chair
Preliminary research suggests two shots show significantly reduced effectiveness against new coronavirus variant
Good venture capitalism should build companies up, developing medicines that deliver public good and profit
Chief executive says more data needed to explain Europe’s higher rate of admissions
Chair of pharma group says support will boost economy as it opens £1bn R&D campus in Cambridge
Vote by European Medicines Agency panel deals setback to controversial $56,000-a-year treatment
New medicines from Pfizer and Merck could take some pressure off hospitals. But will they work on the already vaccinated?
Move comes despite Anglo-Swedish group’s non-profit Covid-19 jab suffering setbacks earlier this year
Stable funding for work on less glamorous diseases would make the system fairer and more resilient
Personalised cancer treatments are among those being developed using a technology once distrusted by big pharma
US pharma group seeks authorisation for first drug of its kind after ‘remarkable’ clinical trial
French group says it is too late to market jab and is working on another with GSK using different technique
International Edition
